A Phase 2/3 interventional study of Gabapentin and Placebo in Pain, Postoperative, sponsored by University of California, Davis. Recruiting at 1 site in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University of California, Davis · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing gabapentin in Pain, Postoperative — 8 open to participants now, 10 under way, 3 of them phase 3. Gabapentin · Pain, Postoperative.
Among the 60 studies testing gabapentin in Pain, Postoperative, this one is the 34th largest by planned enrollment, is one of 5 that started in 2021, is one of 4 in phase 2/3, and was the 43rd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 60 studies testing gabapentin in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
Northwell Health · Sites in United States
Women only · Healthy volunteers
Loma Linda University · Sites in United States
Ages 18–59 · Healthy volunteers
Baylor Research Institute · Sites in United States
Ages 18+
AdventHealth · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 13 · Phase 4 25
First in 2005; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 66 across the 60 interventional studies. Of the 43 that completed or were terminated, 19 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 60 has an industry lead sponsor. The 10 most frequent:
University of California, Davis is the lead sponsor of 811 studies on the registry; 141 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 43 (64%) have results posted.
University of California, Davis has 4 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing gabapentin in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07047040Phase 3Assiut UniversityAnalgesic Efficacy of Pre-operative Dose of Ketorolac and Gabapentin | 2027-10-30 |
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06379425Northwell HealthImpact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries | 2027-01-01 |
| NCT06997016Baylor Research InstituteEnhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients | 2027-06 |
| NCT07840183Northwestern UniversityEpidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 60 studies testing gabapentin in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after thoracic surgery.
We hypothesize that patients who are given gabapentin will need fewer morphine equivalents postoperatively than those who were not given gabapentin
This study is a double-blind, placebo controlled, randomized study to explore the effects of gabapentin peri and post operatively. Physician and families will be blinded to the treatment.
60 subjects will be randomized in a 1:1 ratio to either:
We aim to understand the impact that gabapentin use peri and post operatively has on:
The duration of an individual subject's participation in the study will be 7 days or until the patient is discharged from UC Davis Hospital, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.
Drug: Gabapentin
Given placebo which coincides with the active treatment group
Other: Placebo
Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
Control Arm
Amount of pain medication needed.
Amount of pain medication needed after surgery
Time frame: 7 days post-operative or until discharge, whichever came first
Plan to share: No
Started Aug 2021 (actual). Primary completion is estimated for Dec 2027, 76 months after the start.
Of 49 non-industry phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 76 months is above that.
Counting every sponsor, half of 52 studies reached it within 17 months; a quarter within 10 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
University of California, Davis →